Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer’s Disease

Molecular Neurobiology

Volumn 54, Issue 6, 2017, Pages 4537-4550

  Rodríguez Ruiz, Mar ^a,b   Moreno, Estefanía ^a,b   Moreno Delgado, David ^a,b   Navarro, Gemma ^a,b   Mallol, Josefa ^a,b   Cortés, Antonio ^a,b   Lluís, Carme ^a,b   Canela, Enric I ^a,b   Casadó, Vicent ^a,b   McCormick, Peter J ^a,b,c   Franco, Rafael ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Alzheimers disease; Dementia; G protein coupled receptors; Heteroreceptor complexes; Ionotropic receptor; Neurodegeneration; Neuroprotection; Parkinson s disease; Receptor heteromers; Transgenic animals

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PRESENILIN 1; PROTEIN KINASE B; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE;

ALLOSTERISM; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BRAIN CORTEX; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXCITOTOXICITY; IMMUNOPRECIPITATION; IN SITU PROXIMITY LIGATION ASSAY; MALE; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; RODENT; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CELL DEATH; ENERGY TRANSFER; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; CELL DEATH; CEREBRAL CORTEX; ENERGY TRANSFER; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; MALE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEURONS; NEUROPROTECTION; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, HISTAMINE H3; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 84976493804     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-9995-y     Document Type: Article

References (43)

1. Thathiah A, De Strooper B (2011) The role of G protein-coupled receptors in the pathology of Alzheimer’s disease. Nat Rev Neurosci 12:73–87. doi:10.1038/nrn2977
2. Borchelt DR, Thinakaran G, Eckman CB et al (1997) Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. J Neurosci 1762:10090–10101. doi:10.1523/JNEUROSCI.4147-13.2014
3. Borchelt DR, Thinakaran G, Eckman CB et al (1996) Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17:1005–13
4. Jürgensen S, Antonio LL, Mussi GEA et al (2011) Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta oligomers. J Biol Chem 286:3270–6. doi:10.1074/jbc.M110.177790
5. Cowburn RF, Wiehager B, Trief E et al (1997) Effects of beta-amyloid-(25–35) peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor. Neurochem Res 22:1437–42
6. Ferrada C, Moreno E, Casadó V et al (2009) Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol 157:64–75. doi:10.1111/j.1476-5381.2009.00152.x
7. Moreno E, Vaz SH, Cai N-S et al (2011) Dopamine-galanin receptor heteromers modulate cholinergic neurotransmission in the rat ventral hippocampus. J Neurosci 31:7412–23. doi:10.1523/JNEUROSCI.0191-11.2011
8. Hersi AI, Richard JW, Gaudreau P, Quirion R (1995) Local modulation of hippocampal acetylcholine release by dopamine D1 receptors: a combined receptor autoradiography and in vivo dialysis study. J Neurosci 15:7150–7
9. Seong HJ, Carter AG (2012) D1 receptor modulation of action potential firing in a subpopulation of layer 5 pyramidal neurons in the prefrontal cortex. J Neurosci 32:10516–21. doi:10.1523/JNEUROSCI.1367-12.2012
10. Mcnamara CG, Tejero-Cantero Á, Trouche S et al (2014) Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence. Nat Neurosci 17:1658–60. doi:10.1038/nn.3843
11. Fernández-Novoa L, Cacabelos R (2001) Histamine function in brain disorders. Behav Brain Res 124:213–33
12. Cacabelos R, Yamatodani A, Niigawa H et al (1989) Brain histamine in Alzheimer’s disease. Methods Find Exp Clin Pharmacol 11:353–60
13. Panula P, Rinne J, Kuokkanen K et al (1998) Neuronal histamine deficit in Alzheimer’s disease. Neuroscience 82:993–7
14. Mazurkiewicz-Kwilecki IM, Nsonwah S (1989) Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can J Physiol Pharmacol 67:75–8
15. Medhurst AD, Roberts JC, Lee J et al (2009) Characterization of histamine H3 receptors in Alzheimer’s disease brain and amyloid over-expressing TASTPM mice. Br J Pharmacol 157:130–8. doi:10.1111/j.1476-5381.2008.00075.x
16. Pillot C, Heron A, Cochois V et al (2002) A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 114:173–93
17. Bitner RS, Markosyan S, Nikkel AL, Brioni JD In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer’s disease. Neuropharmacology 60:460–6. doi: 10.1016/j.neuropharm.2010.10.026
18. Brioni JD, Esbenshade TA, Garrison TR et al (2011) Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer’s disease. J Pharmacol Exp Ther 336:38–46. doi:10.1124/jpet.110.166876
19. Chazot PL (2010) Therapeutic potential of histamine H3 receptor antagonists in dementias. Drug News Perspect 23:99–103. doi:10.1358/dnp.2010.23.2.1475899
20. Franco R, Martínez-Pinilla E, Lanciego JLJL, Navarro G (2016) Basic pharmacological and structural evidence for class A G-protein-coupled receptor heteromerization. Front Pharmacol In press:76. doi: 10.3389/fphar.2016.00076
21. Borroto-Escuela DO, Romero-Fernandez W, Garriga P et al (2013) G protein-coupled receptor heterodimerization in the brain. Methods Enzymol 521:281–294. doi:10.1016/B978-0-12-391862-8.00015-6
22. Moreno E, Hoffmann H, Gonzalez-Sepúlveda M et al (2011) Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem 286:5846–54. doi:10.1074/jbc.M110.161489
23. Fiorentini C, Gardoni F, Spano P et al (2003) Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J Biol Chem 278:20196–20202. doi:10.1074/jbc.M213140200
24. Lee FJS, Xue S, Pei L et al (2002) Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111:219–30
25. Wang M, Wong AH, Liu F (2012) Interactions between NMDA and dopamine receptors: a potential therapeutic target. Brain Res 1476:154–63. doi:10.1016/j.brainres.2012.03.029
26. Wilkinson D, Wirth Y, Goebel C (2014) Memantine in patients with moderate to severe Alzheimer’s disease: meta-analyses using realistic definitions of response. Dement Geriatr Cogn Disord 37:71–85. doi:10.1159/000353801
27. Wang D, Jacobs SA, Tsien JZ (2014) Targeting the NMDA receptor subunit NR2B for treating or preventing age-related memory decline. Expert Opin Ther Targets 18:1121–30. doi:10.1517/14728222.2014.941286
28. Navarro G, Cordomí A, Zelman-Femiak M et al (2016) Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs. BMC Biol 14:26. doi:10.1186/s12915-016-0247-4
29. Rodrigues RJ, Almeida T, Díaz-Hernández M et al (2016) Presynaptic P2X1-3 and α3-containing nicotinic receptors assemble into functionally interacting ion channels in the rat hippocampus. Neuropharmacology 105:241–257. doi:10.1016/j.neuropharm.2016.01.022
30. Navarro G, Carriba P, Gandía J et al (2008) Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 8:1088–97. doi:10.1100/tsw.2008.136
31. Navarro G, Moreno E, Aymerich M, et al. (2010) Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci U S A. doi: 10.1073/pnas.1008911107
32. Navarro G, Moreno E, Bonaventura J et al (2013) Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS One 8, e61245. doi:10.1371/journal.pone.0061245
33. Kaphzan H, O’Riordan KJ, Mangan KP et al (2006) NMDA and dopamine converge on the NMDA-receptor to induce ERK activation and synaptic depression in mature hippocampus. PLoS One 1, e138. doi:10.1371/journal.pone.0000138
34. Chen J, Rusnak M, Luedtke RR, Sidhu A (2004) D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem 279:39317–30. doi:10.1074/jbc.M403891200
35. Jeon S-M, Cheon S-M, Bae H-R et al (2010) Selective susceptibility of human dopaminergic neural stem cells to dopamine-induced apoptosis. Exp Neurobiol 19:155–64. doi:10.5607/en.2010.19.3.155
36. Giménez-Xavier P, Gómez-Santos C, Castaño E et al (2006) The decrease of NAD(P)H has a prominent role in dopamine toxicity. Biochim Biophys Acta 1762:564–74. doi:10.1016/j.bbadis.2006.02.003
37. Sidharthan NP, Minchin RF, Butcher NJ (2013) Cytosolic sulfotransferase 1A3 is induced by dopamine and protects neuronal cells from dopamine toxicity: role of D1 receptor-N-methyl-D-aspartate receptor coupling. J Biol Chem 288:34364–74. doi:10.1074/jbc.M113.493239
38. Navarro G, Ferre S, Cordomi A et al (2010) Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J Biol Chem 285:27346–27359. doi:10.1074/jbc.M110.115634
39. Koh JY, Yang LL, Cotman CW (1990) Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533:315–20
40. Le WD, Colom LV, Xie WJ et al (1995) Cell death induced by beta-amyloid 1–40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis. Brain Res 686:49–60
41. Wu J, Anwyl R, Rowan MJ (1995) Beta-amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 6:2409–13
42. Passani MB, Blandina P (1998) Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. Methods Find Exp Clin Pharmacol 20:725–33
43. Grove RA, Harrington CM, Mahler A et al (2014) A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease. Curr Alzheimer Res 11:47–58